ArticleJournal of neuroinflammation2025
Promoting astrocyte-neuron triiodothyronine shuttling attenuates brain damage in neonatal hypoxic-ischemic encephalopathy.
Article in Journal of neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neonatal Hypoxic-Ischemic Encephalopathy: From the Limitations of Therapeutic Hypothermia to Precision Intervention.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundNeonatal Hypoxic-Ischemic Encephalopathy (HIE) is a critical lifelong disabling neonatal disease with insufficient effective therapies. Signaling molecules derived from Astrocyte-Neuron Crosstalk have the potential to improve the prognosis, but relevant HIE research is limited.
methodsWe established hypoxic–ischemic brain damage (HIBD) in postnatal day 7 rat pups using the Rice–Vannucci model, and verified the injury both structurally and hemodynamically by histopathology and laser speckle contrast imaging. Whole-brain single-cell RNA sequencing was performed at P10, and proteomic profiling was conducted on astrocytes subjected to oxygen–glucose deprivation. We charted astrocyte diversity in situ using multiplex immunofluorescence. Thyroid hormones and signaling pathways were quantified by ELISA and Western blotting. Therapeutic efficacy was assessed by histopathology and the Morris water maze.
resultsA brain-wide single-cell transcriptomic atlas revealed a strong transcriptional coupling between astrocytes and neurons. Among astrocytes, we identified and functionally characterized a Dio2⁺Slc1a2⁺ subpopulation with metabolic and neuroprotective features, which was markedly depleted after HIBD. Pseudotime trajectories showed dynamic astrocyte state transitions over time, contextualizing the loss and reparative potential of the Dio2⁺ subpopulation. In vivo and in vitro, boosting astrocytic Dio2 or delivering exogenous Triiodothyronine(T3) enhanced neural repair and improved behavior across both early and long-term stages.
conclusionsWe defined a previously unrecognized neuroprotective astrocyte subpopulation and revealed temporal heterogeneity in astrocytic inflammatory responses in HIE. We also identified a T3-mediated astrocyte–neuron crosstalk mechanism that mitigated HIBD, highlighting a tractable therapeutic avenue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.